| |
European Urology Supplements
Instructions for Authors
General information
Each month European Urology publishes
a wide variety of articles in all areas of urology and related sciences. European Urology Supplements is a separate publication aimed
at the same readership and is sent to all European Urology subscribers. The guidelines below are based on those for European Urology
and have been adapted to the specific aspects of the supplements.
European Urology Supplements publishes proceedings of meetings, symposia
and monographs. The publications require sponsorship. All material for a supplement must go first to the Editor-in-Chief.
Manuscript
Submission
Submissions of the individual articles should be made through the Web site of our online submission system, Editorial
Manager (http://ees.elsevier.com/eursup) .
Editorial Office Contact Information
Questions regarding manuscript submission
may be sent to:
European Urology Editorial Office
Ms. Cathy Pierce, Editorial Office Manager or
Ms. Kerri James, Editorial
Office Assistant
Via Stamira d'Ancona 20
20127 Milan Italy
Telephone: +39 02 2643 6438
Telephone: +39 02 2643 6432
Fax: +39 02 2643 6450
E-mail: european.urology@hsr.it
Manuscripts are received with the explicit understanding
that there has been no duplicate publication or submission elsewhere; all authors have read and approved the manuscript; subject to acceptance,
authors will transfer copyright to the publisher; and there is no ethical problem or conflicts of interest (see below).
Statements
in articles or opinions expressed by any contributor in any article are not the responsibility of the editors or the publishers. The
publisher is not responsible for the loss of manuscripts through circumstances beyond its control.
Accepted manuscripts will be copy-edited
to bring them into conformity with the journal's style. The final version of the manuscript following copy-editing will be sent back
to the author only if specific queries need to be clarified.
It is the author's responsibility to obtain permission to reproduce any
parts of other publications (i.e., tables, figures). Precise reference to the original work must be given in the legends.
Authors
are encouraged to submit figures for the front cover of the journal.
Editorial Policy
Authorship Criteria
The
corresponding author must take responsibility for the integrity of the work as a whole, from inception to published article. Each collaborating
author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Authorship
credit should be based on: substantial contributions to conception and design, acquisition of data, analysis and interpretation of data,
drafting of the article or revising it critically for important intellectual content, statistical analysis, obtaining funding, administrative,
technical or material support, supervision and any other specifics to be declared at publication.
Role of the Corresponding Author
The corresponding author will serve on behalf of all co-authors as the primary correspondent with the editorial office during the submission
and review process. If the manuscript is accepted, the corresponding author will review an edited typescript and proof and will be identified
as the corresponding author in the published article. The corresponding author is responsible for ensuring that all information included
in the Conflict of Interest Policy form is complete and has been agreed on by all authors. ''Acknowledgment'' is the general term for
the list of contributions, credits, and other information included at the end of the text of a manuscript before the references.
Group
Authorship
If authorship is attributed to a group (either solely or in addition to one or more individual authors), all members
of the group must meet the full criteria and requirements for authorship as described above. If that is not the case, a group must designate
one or more individuals as authors or members of a writing group who meet full authorship criteria and requirements. Other group members
who are not authors may be listed in an Acknowledgment.
Conflicts of Interest and Financial Disclosures
Completion of
the European Urology Supplements Conflict of Interest Policy form is an obligatory step of the submission process.
The corresponding
author must collect the relevant information for the Conflict of Interest statements from all co-authors, if any, and submit these via
the Editorial Manager together with the manuscript. If the completed form is not submitted with the manuscript, the manuscript will not
be considered for peer review. Download this form here: form.
A conflict of interest may exist when an author (or the author's institution or employer) has financial or personal relationships or
affiliations that could influence (or bias) the author's decisions, work, or manuscript.
Authors are expected to provide detailed
information about all relevant financial interests and relationships or financial conflicts (e.g., employment/affiliation, grants or
funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending),
particularly those present at the time the research was conducted and through publication, as well as other financial interests (such
as patent applications in preparation), that represent potential future financial gain.
For example, authors of a manuscript about
prostate cancer should report all financial relationships they have with all manufacturers of products used in the management of prostate
cancer, not only those relationships with companies whose specific products are mentioned in the manuscript.
Although many universities
and other institutions have established policies and thresholds for reporting financial interests and other conflicts of interest, European
Urology requires complete disclosure of all relevant financial relationships and potential financial conflicts of interest, regardless
of amount or value.
All disclosures of any potential conflicts of interest, including specific financial interests and relationships
and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript
will be disclosed by the corresponding author on behalf of each co-author, if any, as part of the submission process. Likewise, authors
without conflicts of interest, will be requested to state so as part of the submission process.
If authors are uncertain about what
constitutes a relevant financial interest or relationship, they should contact the editorial office.
Failure to include this information
in the Conflict of Interest Policy form
will prohibit commencement of the review process of the manuscript.
For all accepted manuscripts, each author's disclosures of conflicts
of interest and relevant financial interests and affiliations and declarations of no such interests will be published.
The policy
requesting disclosure of conflicts of interest applies for all manuscript submissions. If an author's disclosure of potential conflicts
of interest is determined to be inaccurate or incomplete after publication, a correction will be published to rectify the original published
disclosure statement.
Authors are also required to report detailed information regarding all financial and material support for the
research and work, including but not limited to grant support, funding sources, and provision of equipment and supplies as part of the
submission process. For all accepted manuscripts, each author's source of funding will be published.
Funding/Support and Role
of Sponsor
All financial and material support for the research and work will be requested to be clearly and completely identified
as part of the submission process. The specific role of the funding organization or sponsor in each of the following should be specified:
''design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval
of the manuscript.'' The corresponding author is responsible for acknowledging this on the Conflict of Interest Policy form to be sent
to the European Urology Supplements contact persons at Elsevier at the time of submission.
Data Access and Responsibility
For all reports (regardless of funding source) containing original data, at least one named author (e.g., the principal investigator)
who is independent of any commercial funder should indicate that she or he ''had full access to all the data in the study and takes responsibility
for the integrity of the data and the accuracy of the data analysis.'' This exact statement will be requested as part of the submission
process. Modified statements or generic statements indicating that all authors had such access are not acceptable.
Duplicate/Previous
Publication or Submission
Manuscripts are considered with the understanding that they have not been published previously in print
or electronic format and are not under consideration by another publication or electronic medium. Copies of related or possibly duplicative
materials (ie, those containing substantially similar content or using the same or similar data) that have been previously published
or are under consideration elsewhere must be provided at the time of manuscript submission.
Ethical Approval of Studies and Informed
Consent
For human or animal experimental investigations, formal review and approval, or review and waiver, by an appropriate
institutional review board or ethics committee is required and should be described in the Methods section. For those investigators who
do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. For investigations
of human subjects, state in the Methods section the manner in which informed consent was obtained from the study participants (ie, oral
or written).
Personal Communications and Unpublished Data
A signed statement of permission should be included from each
individual identified as a source of information in a personal communication or as a source for unpublished data, and the date of communication
and whether the communication was written or oral should be specified.
Previous Presentation or Release of Information
A complete report following presentation at a meeting or publication of preliminary findings elsewhere (e.g., an abstract) is eligible
for consideration for publication.
Unauthorized Use
Published manuscripts become the permanent property of the EAU and
may not be published elsewhere in whole or in part without written permission. Unauthorized use of the European Urology name, logo, or
any content for commercial purposes or to promote commercial goods and services (in any format, including print, video, audio, and digital)
is not permitted by the EAU.
Editorial Review and Publication
The peer review process is carefully supervised by the editors
of the journal. Manuscripts will be considered initially by the editors to assess whether they reach a priority score justifying peer
review. Manuscripts considered of interest by the editors will be reviewed by internationally recognized experts on the subject. When
necessary, a biostatistician will also review manuscripts. Reviewers are allotted 14 days to complete their reviews. The reviewers will
not be blinded to the names of the authors or the institution from which the manuscripts have been sent. Authors will be asked to incorporate
the requested changes for the revision in 5 working days. The final decision to accept or reject a manuscript will be made by the Editor-in-Chief
in conjunction with the Associate Editors.
Types of Articles
Original articles
These manuscripts typically report
on basic and translational research, epidemiology, pathophysiology, diagnosis, medical or surgical treatment, and minimally invasive
therapy related to urologic diseases.
Each manuscript should clearly state an objective or hypothesis; the design and methods (including
the study setting and dates, patients or participants with inclusion and exclusion criteria and/or participation or response rates, or
data sources, and how these were selected for the study); the essential features of any interventions; the main outcome measures; the
main results of the study; a discussion section placing the results in context with the published literature and addressing study limitations;
and the conclusions. Data included in research reports should be as timely and current as possible.
The format of the original article
should be as follows
Abstract
Provide a structured abstract no longer than 300 words with the following sections: Background; Objective;
Design, Setting, and Participants; Intervention(s) (if applicable); Measurements; Results and Limitations; Conclusions.
For brevity,
parts of the abstract may be written as phrases rather than complete sentences. Each section should include the following content (see
abstract structure details below):
- Background: The abstract should begin with a sentence or two explaining the clinical (or
other) importance of the study question.
- Objective: State the precise objective or study question addressed in the manuscript
(e.g., ''To determine whether. . .''). If more than one objective is addressed, the main objective should be indicated and only key secondary
objectives stated.
- Design, Setting, and Participants: Describe the basic design of the study. State the years of the study
and the duration of follow-up. Describe the study setting to assist readers to determine the applicability of the report to other circumstances,
for example, general community, a primary care or referral center, private or institutional practice, or ambulatory or hospitalized care.
State the clinical disorders, important eligibility criteria, and key sociodemographic features of patients. The numbers of participants
and how they were selected should be provided. In follow-up studies, the proportion of participants who completed the study must be indicated.
In intervention studies, the number of patients withdrawn because of adverse effects should be given. For selection procedures, these
terms should be used, if appropriate: random sample (where random refers to a formal, randomized selection in which all eligible individuals
have a fixed and usually equal chance of selection); population-based sample; referred sample; consecutive sample; volunteer sample;
convenience sample.
- Intervention(s) (if applicable): The essential features of any interventions (surgical or medical) should
be described. The nonproprietary drug or device names should be used unless the specific trade name is essential to the study.
- Measurements: Indicate the primary and secondary study outcome measurement(s).
- Results and Limitations: The main outcomes
of the study should be reported and quantified. Complications or sequelae of the interventions used must be detailed. Particular attention
must be given to statistical analysis. All randomized controlled trials should include the results of intention-to-treat analysis, and
all surveys should include response rates. Limitations of the study should be acknowledged.
- Conclusions: Provide only conclusions
of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.
Indicate whether additional study is required before the information should be used in usual clinical settings. Give equal emphasis to
positive and negative findings of equal scientific merit.
- Trial Registration: For clinical trials, the name of the trial registry,
registration number, and URL of the registry must be included.
Text
The text of the manuscript should be divided
as follows: Introduction; Material (Patients) and Methods; Results; Discussion; Conclusions.
- Number of references should be
limited to 30.
- Maximum word count is 3000, including the abstract but not including the references, tables, figures, or legends.
Should the word count exceed this limit, please consult with the Editorial Office.
Take Home Message
Two or three
sentences (no more than 40 words) summarizing the main message expressed in the article must be uploaded as a separate file.
Ethical
Considerations and Registration of Clinical Trials
Trial Registration: As a member of the International Committee of Medical
Journal Editors (ICMJE), European Urology requires, as a condition of consideration for publication, registration of all trials in a
public trials registry that is acceptable to the ICMJE and that requires the minimum registration data set as described by the ICMJE.
Acceptable trial registries include the following:
http://www.actr.org.au
http://www.clinicaltrials.gov
http://isrctn.org
http://www.trialregister.nl/trialreg/index.asp
http://www.umin.ac.jp/ctr
For this purpose, a clinical trial is any study that prospectively assigns human subjects to intervention or comparison groups to evaluate
the cause and- effect relationship between a medical/surgical intervention and a health outcome. All clinical trials, regardless of when
they were completed, and secondary analyses of original clinical trials must be registered before submission of a manuscript based on
the trial. For clinical trials starting patient enrollment after July 2005, trials must be registered before onset of enrollment. Studies
designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt. Trial registry name,
registration identification number, and the URL for the registry should be included at the end of abstract.
CONSORT Flow Diagram and Checklist: Manuscripts reporting the results of randomized controlled trials should include
the CONSORT flow diagram showing the progress of patients throughout the trial. The CONSORT
checklist also should be completed and submitted with the manuscript and can be found on http://www.europeanurology.com
.
Review Articles
These are reviews that systematically find, select, critique, and synthesize evidence relevant to well
defined questions about diagnosis, therapy, and prognosis. The format of the review article should be as follows:
Abstract
Provide a structured abstract no longer than 300 words with the following sections: Context, Objective, Evidence Acquisition, Evidence
Synthesis, Conclusion (see abstract structure details below.)
- Context: Include one or two sentences describing the clinical
question or issue and its importance in clinical practice or public health.
- Objective: State the precise primary objective
of the review. Indicate whether the review emphasizes factors such as cause, diagnosis, prognosis, therapy, or prevention and include
information about the specific population, intervention, exposure, and tests or outcomes that are being reviewed.
- Evidence
Acquisition: Describe the data sources used, including the search strategies, years searched, and other sources of material, such as
subsequent reference searches of retrieved articles. Methods used for quality assessment and inclusion of identified articles should
be explained.
- Evidence Synthesis: The major findings of the review of the clinical issue or topic should be addressed in an
evidence-based, objective, and balanced fashion, with the highest quality evidence available receiving the greatest emphasis.
- Conclusions:
The conclusions should clearly answer the questions posed if applicable, be based on available evidence, and emphasize how clinicians
should apply current knowledge.
Text
The text of the manuscript should be divided as follows: Introduction, Evidence
Acquisition, Evidence Synthesis, Conclusions.
- Maximum word count is 4000, including the abstract but not including the references,
tables, figures, or legends. Should the word count exceed this limit, please consult with the Editorial Office.
- Number of references
should be limited to 50.
Take Home Message
Two or three sentences (no more than 40 words) summarizing the main
message expressed in the article must be uploaded as a separate file.
EU-ACME articles
Selected articles per issue will
be designated by the Editor-in-Chief at the time of final acceptance as EU-ACME articles. The authors will be asked to provide six EU-ACME
questions for these articles based on the information provided in the article. Four possible answers should be provided for each question,
with only one of them being the correct one. The correct answer should be explained in text limited to 50 words; up to three references
are allowed to support this explanation. (Specifically dedicated instructions for authors for these questions and answers will be provided.)
The questions and answers will not be printed in the journal but will be available at http://acme.uroweb.org/europeanurology/
Manuscript Preparation and Submission Requirements
Manuscript Submission
Original manuscripts written in English
should be submitted through the web site of our online submission system, Editorial Manager (http://ees.elsevier.com/eursup),
in Word, WordPerfect, or LaTeX formats for text and EPS or TIFF for illustrations. Authors may also check the status of submitted articles
at this site. At the time of submission, complete contact information (postal/mail address, e-mail address, telephone and fax numbers)
for the corresponding author is required. First and last names, e-mail addresses, and institutional affiliations of all co-authors are
also required. Manuscripts submitted through the online system should not also be submitted by mail or e-mail. Once the manuscript is
submitted online, the corresponding author will receive a manuscript number and will be able to follow the status of the manuscript through
the online system.
Manuscript Components
Include a title page, abstract, text, references, and as appropriate, figure
legends, tables, and figures, take home message (for original and review articles). Start each of these sections on a new page, numbered
consecutively, beginning with the title page. Please check the instructions per article type listed above.
Manuscript File Formats
For submission and review, acceptable manuscript file formats include Word, WordPerfect, EPS, Text, Postscript, or RTF format. Use 12-point
font size, double-space text, and leave right margins unjustified with margins of at least 2.5 cm. Each page should be numbered in the
upper right corner, beginning on p. 2. Add continuous line numbering.
Title Page
The title page should include a word
count for the text and abstract separately. Authors' full names, highest academic degrees, and affiliations should also be included (see
list below). If an author s affiliation has changed since the work was done, the new affiliation also should be listed. For indexing
purposes, 3—10 key words should be supplied in alphabetical order (see example below)
- Title
- Authors (first name
and initials followed by surname, e.g., Juan X. Alvarez)
- Affiliations (if multiple affiliations are listed, indicate with lowercase
letter footnotes following the respective authors names)
- Contact information for corresponding author, including full mailing
address, telephone number, fax number, and e-mail address
- For indexing purposes, 3—10 keywords should be supplied (in
alphabetical order) as follows: Keywords Benign prostatic hyperplasia; Doxazosin; Lower urinary tract symptoms
- Word count of
text: include the abstract but not the references in this count
- Word count of the abstract (please remember Abstracts cannot
exceed 300 words)
Abstracts
Include a structured abstract of no more than 300 words for original and review articles.
(See instructions above for preparing structured abstracts.) Abstracts are not required for editorials. No information should be reported
in the abstract that does not appear in the text of the manuscript.
Headings
Do not use automatically generated numbering
or bulleting systems or hidden text (e.g., for headings, references, footnotes, lists).
Units of Measurement
Units of
measurements must conform to the Système International (SI): year(s), yr; month(s), mo; days, d; hours, h; minutes, min; seconds,
s; grams, g; liters, l; meters, m; sample size, n; degrees of freedom, df; standard error of the mean, SE; standard deviation, SD; probability,
p.
Numerals and Abbreviations
Use numerals for all values greater than ten and those followed by a unit; otherwise, spell
out (e.g., 18 patients, 0.8 g/ml, 47%, 37 8C, six cases). Spell out numbers at the beginning of a sentence. Abbreviations must be defined
at first use in each of the following: text, tables, and figure legends.
Conflict of Interest statements
The European
Urology Supplements Conflict of Interest Policy form needs to be completed and uploaded together with the submission of the manuscript.
The Conflict of Interest statements will be inserted by the copy-editor at the end of the article, before the references.
Acknowledgments
The Acknowledgments section is the general term for the list of contributions, credits, and other information included at the end of
the text of a manuscript but before the references. Authors should obtain written permission to include the names of individuals in the
Acknowledgment section.
References
In the text, references should be cited in numerical order, with citation numbers placed
in square brackets.
Personal communications (pers. comm.) and unpublished data (unpubl. data) are mentioned only in the text: (pers.
comm., A. Brown, Ithaca, New York, USA).
Each reference number should correspond to a single published source.
List all authors
up to six; for more than six authors list the first three followed by et al.
Use Index Medicus abbreviations for journals. Provide
full page ranges, using the abbreviated format shown below.
[1] MacDonald R, Fink HA, Huckabay C, Monga M, Wilt TJ. Botulinum toxin
for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects. Spinal
Cord 2007;45:535—41.
[2] Filocamo M, Li Marzi V, Del Popolo G, et al. Pharmacologic treatment in postprostatectomy stress urinary
incontinence. Eur Urol 2007;51:1559—64.
[3] Hatzimouratidis K, Hatzichristou D. Testosterone and erectile function: an unresolved
enigma. Eur Urol 2007;52:26—8.
Book
[1] King RC, Stansfield WD. A dictionary of genetics, ed. 3. New York: Oxford University
Press; 2002.
Book chapter
[1] Hunskaar S, Burgio K, Diokno AC, Herzog AR, Hjalmas K, Lapitan MC. Epidemiology and natural history
of urinary incontinence. In: Abrams P, Cardoza L, Khoury S, Wein A, editors. Incontinence: 2nd International Consultation on Incontinence,
ed. 2. Plymouth, UK: Health Publications, 2002. p. 165—201.
Thesis or Dissertation
[1] Kato H. Neuroendocrine cells: their
effect on the development of benign prostatic hyperplasia. Ph.D. diss. [MS thesis], University of Tokyo Medical School, Tokyo, 1997.
Tables
- Compose tables in a word-processing program; do not insert as graphic elements. Number tables with Arabic numerals
in the order they appear in the text. Place each table on a separate page.
- Provide a title at the top of each table.
- Explain abbreviations and include any other comments in a note at the bottom of each table.
Figures
- Figures
must supplement, not duplicate, the tables and text.
- Illustrations must clearly convey their message and be of high quality
and sufficient size and clarity (especially lettering, arrows, and data points) to be interpretable when reduced for publication.
- Number figures with Arabic numerals in the order they appear in the text.
- Provide a separate list of figure legends at
the end of the text; do not place legends on the figures.
- Do not embed artwork within the text; figures should be supplied as
separate files.
- Guidelines for submitting figures in an electronic format can be found at http://www.elsevier.com/wps/find/authors.authors/authorartworkinstructions/
under Artwork Instructions.
Manuscript Checklist
Prior to submitting a manuscript to European Urology Supplements,
authors must ensure that each requirement listed above is met. Manuscripts that do not meet these requirements will be returned to the
author without review.
Proofs
Unless otherwise indicated, proofs are sent in PDF format via e-mail to the central contact
person responsible for coordinating the checking of the proofs. Proofs must be returned within the deadline specified by the Publisher.
Proofs can be accompanied by separate queries. Authors should not contact the editorial office of the journal with regard to these queries.
All queries must be answered directly on the page proofs. If corrections are not made and returned to Elsevier by the specified deadline,
the article will be published as is. |
| |
|
